NCT07147023 (BRIDGE-SIC) is a NA clinical trial of LLM SIC Summary Email in Advanced Cancer, sponsored by Dana-Farber Cancer Institute.

Who is sponsoring NCT07147023?

NCT07147023 is sponsored by Dana-Farber Cancer Institute.

What drugs are being tested in NCT07147023?

Interventions in NCT07147023: LLM SIC Summary Email.

What condition does NCT07147023 study?

NCT07147023 studies Advanced Cancer, Cancer, End of Life.

Is NCT07147023 still recruiting?

NCT07147023 is currently active, enrolled. Last updated 9 February 2026.

Last reviewed 2026-02-09 · How we verify

NCT07147023: BRIDGE-SIC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Better Real-time Information on Documentation of Goals of Care for Engagement in Serious Illness Communication

Active, enrolled NA Last updated 9 February 2026

What this trial tests

NA trial testing LLM SIC Summary Email in Advanced Cancer in 60 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

15 September 2025

Primary endpoint
31 March 2026

31 October 2026

Quick facts

Lead sponsor	Dana-Farber Cancer Institute
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	60
Start date	15 September 2025
Primary completion	31 March 2026
Estimated completion	31 October 2026
Sites	2 locations across United States

Drugs / interventions tested

LLM SIC Summary Email

Conditions studied

Advanced Cancer — all drugs for Advanced Cancer →
Cancer — all drugs for Cancer →
End of Life — all drugs for End of Life →

Sponsor

Dana-Farber Cancer Institute

Who can join

18 and older, any sex, with Advanced Cancer or Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to test the accuracy of Large Language Model-generated serious illness communication (SIC) summaries, the feasibility of delivering the SIC summaries, and to collect perspectives on the SIC summaries from clinicians and participants with cancer. Large Language Models (LLMs) are artificial intelligence programs that can perform various natural language processing tasks.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Advanced Cancer

Currently open trials in the same condition.

NCT07393529 — A Pilot Randomized Controlled Trial of a Social Network Intervention · NA · recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07246954 — A Chaplain-clinician Led Spiritual Care (PEACE) Intervention on Spiritual/Religious Beliefs Related to Medical Care in P · NA · recruiting
NCT06346197 — Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas · Phase 3 · recruiting
NCT07105033 — Development and Pilot Trial of Focused ACT (FACT) for Patients With Advanced Cancer · NA · recruiting

Other Dana-Farber Cancer Institute trials

Trials by the same sponsor.

NCT07519200 — Sexual Health and Rehabilitation for Women With Metastatic Breast Cancer (SHARE-MC): An Educational Intervention · NA · not yet recruiting
NCT07499999 — Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk fo · Phase 2 · not yet recruiting
NCT05825469 — Development and Testing of Nutritional Algorithms (NACHO) · NA · not yet recruiting
NCT07516353 — my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults · NA · not yet recruiting
NCT07513324 — Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07147023 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dana-Farber Cancer Institute
Last refreshed: 9 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07147023.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing